<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>TNFalpha levels are elevated in the marrows of patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and are associated with high rates of <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, which contributes to hematopoietic failure </plain></SENT>
<SENT sid="1" pm="."><plain>We observed that exposure of human marrow stroma cell lines <z:chebi fb="0" ids="30608,30611">HS5</z:chebi> and HS27a to TNFalpha increases levels of IL-32 mRNA </plain></SENT>
<SENT sid="2" pm="."><plain>IL-32, in turn, induces TNFalpha </plain></SENT>
<SENT sid="3" pm="."><plain>Marrow stroma from patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> expressed 14- to 17-fold higher levels of IL-32 mRNA than healthy controls </plain></SENT>
<SENT sid="4" pm="."><plain>In contrast, cells from patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>) expressed only one tenth the level of IL-32 measured in healthy controls </plain></SENT>
<SENT sid="5" pm="."><plain>Human KG1a <z:hpo ids='HP_0001909'>leukemia</z:hpo> cells underwent <z:mpath ids='MPATH_3'>apoptosis</z:mpath> when cocultured with <z:chebi fb="0" ids="30608,30611">HS5</z:chebi> stromal cells, but knockdown of IL-32 in the stromal cells by using siRNA abrogated <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in the <z:hpo ids='HP_0001909'>leukemia</z:hpo> cells </plain></SENT>
<SENT sid="6" pm="."><plain>IL-32 knockdown cells also showed dysregulation of VEGF and other cytokines </plain></SENT>
<SENT sid="7" pm="."><plain>Furthermore, CD56(+) natural killer cells from patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> expressed IL-32 at lower levels than controls and exhibited reduced cytotoxic activity, which was unaffected by IL-2 treatment </plain></SENT>
<SENT sid="8" pm="."><plain>We propose that IL-32 is a marrow stromal marker that distinguishes patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>Furthermore, IL-32 appears to contribute to the pathophysiology of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and may be a therapeutic target </plain></SENT>
</text></document>